Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments

Source: cancer network, November 2020

Jason Luke, MD, FACP of the UPMC Hillman Cancer Center spoke with CancerNetwork about the latest developments regarding melanocytes, dysregulated pathways and melanoma at the SMR Conference.

Well it’s become quite clear from a number of elegant studies from people like Boris Bastian and Hunter Shane about the progression of melanocytes picking up serial dysregulated oncogenes and overexpression of certain pathways.

One of the surprising features about melanoma is that the BRAF that we target with BRAF-directed targeted therapies actually develops very early in melanocytes.